Results 21 to 30 of about 5,782,005 (384)
Epidemiology, Staging, and Management of Multiple Myeloma
Medical Science, 2021 Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the ...
S. Padala +7 more
semanticscholar +1 more source
Nature Communications, 2022 The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being ...
Yuen Lam Dora Ng +16 more
semanticscholar +1 more source
Technology in Cancer Research & Treatment, 2020 Objective: The present study aimed to explore the correlation of protein kinase D 1 with prognosis in bortezomib-treated multiple myeloma patients and further investigate the effect of protein kinase D 1 knockdown on drug sensitivity to bortezomib in ...
Xuesong Li MM, Ying Yang MM, Xue Yi MM
doaj +1 more source
Technology in Cancer Research & Treatment, 2020 Objective: The present study aimed to detect A-kinase interacting protein 1 expression and further explore the association of A-kinase interacting protein 1 with clinical features and prognosis in patients with multiple myeloma.
Wei Wang MD +4 more
doaj +1 more source
Blood Cancer Journal, 2021 Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect and isotype M-proteins ...
D. Murray +12 more
semanticscholar +1 more source
Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells [PDF]
, 2017 Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow (BM). Recently, several studies have highlighted the role of pathogens in either promoting or dampening malignancies of unrelated origin.
Bertrand, Mathieu +11 more
core +3 more sources
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells. role of cMYC-IRF4-miR-125b interplay [PDF]
, 2016 Background: Anticancer immune responses may contribute to the control of tumors after conventional chemotherapy and different observations have indicated that chemotherapeutic agents can induce immune responses resulting in cancer cell death and immune ...
Abruzzese, MARIA PIA +13 more
core +13 more sources
Blood, 2019 Three proteasome inhibitors have garnered regulatory approvals in various multiple myeloma settings; but drug resistance is an emerging challenge, prompting interest in blocking upstream components of the ubiquitin-proteasome pathway. One such attractive
J. Zhuang +18 more
semanticscholar +1 more source
Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma [PDF]
, 2016 Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored.
Fillerová, Regina +9 more
core +1 more source
Leukemia, 2018 Bromodomain and extraterminal (BET) domain containing protein (BRD)-4 modulates the expression of oncogenes such as c-myc, and is a promising therapeutic target in diverse cancer types.
Xiaohui Zhang +22 more
semanticscholar +1 more source